Halberd Corp. is a development stage company, which engages in the research and development of antibodies and devices for the prevention, detection, and treatment of neurodegenerative diseases. It offers patented extracorporeal treatment that is applicable to various blood-borne and neurologic diseases such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer's Disease, and Parkinson's Disease. The company was founded by Mark Sven Lundquist and John Christopher Maddox on January 26, 2009 and is headquartered in Jackson Center, PA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company